Company Analysis
Sign in

Amarin Corporation plc (AMRN)

Nasdaq: AMRN · Pharmaceutical Preparations · Dublin 2 · filing with the SEC since 1998
Full chart Alerts Compare
Grade4.9
◀ Past 4.9● Present 5.2▶ Future 4.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

141 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Amarin Corporation plc’s names, not what it holds today.

Patents granted
141
141 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 5 in 2023
Applications published
273
3 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals41
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
AMARIN PHARMACEUTICALS IRELAND LIMITED a subsidiary
IE, as the owner printed on each patent
140 granted
65 published
Amarin Pharmaceuticals Ireland Limited a subsidiary
named as the applicant on its applications, in IE
0 granted
187 published
Amarin Pharma, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
21 published
Names not counted (2)
AMARIN CORP PLC\UK
Most of its patents print IE; this name counts in GB, US. 1 granted and 5 published under it are not counted.
AMARIN DEVELOPMENT AB
Most of its patents print SE; this name counts in GB, US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,427,134Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutterPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Mar 11, 202512,246,003Methods of reducing the risk of cardiovascular events in a subjectPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Dec 24, 202412,171,738Compositions and methods for lowering triglyceridesPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
May 21, 202411,986,452Methods of reducing the risk of heart failurePharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Aug 8, 202311,717,504Methods of reducing the risk of cardiovascular events in a subjectPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Aug 1, 202311,712,429Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivityPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Aug 1, 202311,712,428Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivityPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Jul 4, 202311,690,820Methods of treating mixed dyslipidemiaPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Jan 10, 202311,547,710Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statinPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Oct 11, 202211,464,757Compositions and methods for lowering triglyceridesPharmaceuticalsAMARIN PHARMACEUTICALS IRELAND LIMITED
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 3, 20252025/0213517METHODS OF REDUCING THE RISK OF HEART FAILUREPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
Jun 12, 20252025/0186386METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A STATIN-TREATED SUBJECTPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
May 8, 20252025/0144061METHODS OF TREATING MIXED DYSLIPIDEMIAPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
Jul 4, 20242024/0216322COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASEPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
May 30, 20242024/0173285COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECTPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
May 23, 20242024/0165066LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENTPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
May 9, 20242024/0148683STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAMEPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
Jan 25, 20242024/0024277METHODS OF TREATING HYPERTRIGLYCERIDEMIAPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
Jan 25, 20242024/0024269PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAMEPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
Jan 18, 20242024/0016803PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND DERIVATIVES THEREOF AND A STATINPharmaceuticalsAmarin Pharmaceuticals Ireland Limited
What it applied for, 2024 to 2025: Pharmaceuticals 10.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AMRN · research, not advice